| 引用本文: |
唐蔚,潘博,杨晓,曾再蓉,宋程.益肾活血止痛方联合盐酸羟考酮缓释片治疗肾虚血瘀型骨转移癌痛临床观察[J].湖南中医药大学学报,2018,38(7):806-810[点击复制] |
|
| |
|
|
| 本文已被：浏览 1786次 下载 540次 |
| 益肾活血止痛方联合盐酸羟考酮缓释片治疗肾虚血瘀型骨转移癌痛临床观察 |
| 唐蔚,潘博,杨晓,曾再蓉,宋程 |
| (湖南省中医药研究院附属医院, 湖南 长沙 410006;湖南中医药大学, 湖南 长沙 410208;湖南省肿瘤医院, 湖南 长沙 410013) |
| 摘要: |
| 目的 观察益肾活血止痛方联合盐酸羟考酮缓释片治疗肾虚血瘀型骨转移癌痛的临床疗效。方法 选取本院肿瘤科骨转移癌痛患者60例按随机数字表法分为观察组和对照组，每组各30例。对照组单纯予盐酸羟考酮缓释片治疗；观察组在对照组基础上联合益肾活血止痛方治疗，2组均治疗14 d。观察患者疼痛数字评分（numerical rating scale，NRS）、疼痛缓解度、盐酸羟考酮缓释片服用情况（药物维持剂量，滴定达维持剂量时间）、生存质量评分（kamofsky，KPS），并记录不良反应情况。结果 与本组治疗前比较，两组NRS评分均呈进行性下降（P<0.05），观察组用药14 d后NRS评分低于对照组（P<0.05）；用药14 d后，与治疗3天（d3）比较，两组疼痛控制有效率显著提高（P<0.05），与同时段对照组比较，在服药第7、14 d后，观察组疼痛控制有效率明显提高（P<0.05或P<0.01）；与对照组比较，观察组患者持续服用盐酸羟考酮缓释片剂量明显减少（P<0.05），且服用盐酸羟考酮缓释片滴定达维持剂量时间缩短（P<0.05）；与治疗前相比，两组KPS评分均明显升高（P<0.05），且观察组KPS评分高于对照组（P<0.05）。结论 益肾活血止痛方联合盐酸羟考酮缓释片治疗肾虚血瘀型骨转移癌痛具有较好的临床疗效。 |
| 关键词: 益肾活血止痛方 肾虚血瘀证 骨转移癌痛 临床疗效 |
| DOI：10.3969/j.issn.1674-070X.2018.07.021 |
| 投稿时间：2017-11-22 |
| 基金项目:湖南省中医药科技计划重点项目（201750）；湖南省中医药研究院科技计划重点项目（201402）。 |
|
| Clinical Effect of Yishen Huoxue Zhitong Prescription Combined with Oxycodone Hydrochloride Sustained-release Tablets in Treatment of Bone Metastatic Cancer Pain with Kidney Deficiency and Blood Stasis Syndrome |
| TANG Wei,PAN Bo,YANG Xiao,ZENG Zairong,SONG Cheng |
| (The Affiliated Hospital of Hunan Academy of Chinese Medicine, Changsha, Hunan 410006, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Hunan Cancer Hospital, Changsha, Hunan 410013, China) |
| Abstract: |
| Objective To investigate the clinical effect of Yishen Huoxue Zhitong Prescription combined with oxycodone hydrochloride sustained-release tablets in the treatment of bone metastatic cancer pain with kidney deficiency and blood stasis syndrome. Methods A total of 60 patients with bone metastatic cancer pain who were treated in Department of Oncology in our hospital were divided into observation group and control group using a random number table, with 30 patients in each group. The patients in the observation group were given Yishen Huoxue Zhitong Prescription combined with oxycodone hydrochloride sustained-release tablets, and those in the control group were given oxycodone hydrochloride sustained-release tablets alone. The course of treatment was 14 days for both groups. Numerical Rating Scale(NRS) score, pain relief, administration of oxycodone hydrochloride sustained-release tablets(maintenance dose and time to reach maintenance dose), and Karnofsky Performance Scale (KPS) score were observed for both groups, and adverse events were recorded. Results Both groups had a progressive reduction in NRS score after treatment (P<0.05), and after 14 days of medication, the observation group had a significantly lower NRS score than the control group (P<0.05). After 14 days of medication, both groups had a significant increase in pain control rate (P<0.05), and on days 7 and 14 of medication, the observation group had a significant increase in pain control rate compared with the control group(P<0.05 or P<0.01). Compared with the control group, the observation group had a significant reduction in the maintenance dose of oxycodone hydrochloride sustained-release tablets(P<0.05) and a significantly shortened time to reach maintenance dose(P<0.05). Both groups had a significant increase in KPS score after treatment(P<0.05), and the observation group had a significantly higher KPS score than the control group(P<0.05). Conclusion Yishen Huoxue Zhitong Prescription combined with oxycodone hydrochloride sustained-release tablets has a good clinical effect in the treatment of bone metastatic cancer pain with kidney deficiency and blood stasis syndrome. |
| Key words: Yishen Huoxue Zhitong Prescription bone metastatic cancer pain kidney deficiency and blood stasis syndrome clinical effect |
|
二维码（扫一下试试看！） |
|
|
|
|
